Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges

被引：2

作者：

Lim, Jeong Uk ^{[1
]}

Jung, Junyang ^{[2
]}

Kim, Yeon Wook ^{[3
]}

Kim, Chi Young ^{[4
]}

Lee, Sang Hoon ^{[5
]}

Park, Dong Won ^{[6
]}

Choi, Sue In ^{[7
]}

Ji, Wonjun ^{[8
]}

Yeo, Chang Dong ^{[9
]}

Lee, Seung Hyeun ^{[10
,11
]}

机构：

[1] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm & Crit Care Med, Seoul 06591, South Korea

[2] Kyung Hee Univ, Coll Med, Dept Anat & Neurobiol, Seoul 02447, South Korea

[3] Seoul Natl Univ Bundang Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seongnam 13620, South Korea

[4] Yonsei Univ, Coll Med, Dept Internal Med, Div Pulmonol, Seoul 03722, South Korea

[5] Yonsei Univ, Severance Hosp, Coll Med, Inst Chest Dis,Dept Internal Med,Div Pulm & Crit C, Seoul 03722, South Korea

[6] Hanyang Univ, Coll Med, Dept Internal Med, Div Pulm Med & Allergy, Seoul 04763, South Korea

[7] Korea Univ, Coll Med, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Seoul 02841, South Korea

[8] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Internal Med,Div Pulmonol & Crit Care Med, Seoul 44610, South Korea

[9] Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Crit Care & Sleep Med, Seoul 03083, South Korea

[10] Kyung Hee Univ, Coll Med, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Seoul 02447, South Korea

[11] Kyung Hee Univ, Grad Sch, Dept Precis Med, Seoul 02447, South Korea

来源：

BIOMEDICINES | 2025年 / 13卷 / 02期

基金：

新加坡国家研究基金会;

关键词：

epidermal growth factor receptor mutation; lung cancer; resistance; tumor microenvironment; biomarker; EPITHELIAL-MESENCHYMAL TRANSITION; HIGH PD-L1 EXPRESSION; GROWTH-FACTOR-BETA; ACQUIRED-RESISTANCE; PLUS OSIMERTINIB; ADVANCED NSCLC; ADENOCARCINOMA; AMPLIFICATION; GEFITINIB; CHEMOTHERAPY;

D O I：

10.3390/biomedicines13020470

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Tyrosine kinase inhibitors (TKIs) have transformed the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. However, treatment resistance remains a major challenge in clinical practice. The tumor microenvironment (TME) is a complex system composed of tumor cells, immune and non-immune cells, and non-cellular components. Evidence indicates that dynamic changes in TME during TKI treatment are associated with the development of resistance. Research has focused on identifying how each component of the TME interacts with tumors and TKIs to understand therapeutic targets that could address TKI resistance. In this review, we describe how TME components, such as immune cells, fibroblasts, blood vessels, immune checkpoint proteins, and cytokines, interact with EGFR-mutant tumors and how they can promote resistance to TKIs. Furthermore, we discuss potential strategies targeting TME as a novel therapeutic approach.

引用

页数：31

共 246 条

[1]

Ahn MJ, 2022, J THORAC ONCOL, V17, pS469

[2] Dysregulated Signalling Pathways Driving Anticancer Drug Resistance [J].